[go: up one dir, main page]

CA3102967A1 - Composition et procede d'inhalation - Google Patents

Composition et procede d'inhalation Download PDF

Info

Publication number
CA3102967A1
CA3102967A1 CA3102967A CA3102967A CA3102967A1 CA 3102967 A1 CA3102967 A1 CA 3102967A1 CA 3102967 A CA3102967 A CA 3102967A CA 3102967 A CA3102967 A CA 3102967A CA 3102967 A1 CA3102967 A1 CA 3102967A1
Authority
CA
Canada
Prior art keywords
dry powder
powder composition
pharmaceutically acceptable
acceptable carrier
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102967A
Other languages
English (en)
Inventor
Joseph J. Guarneri
Nikhil AMIN
Marshall L. Grant
John J. Freeman
Kelly S. Kraft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CA3102967A1 publication Critical patent/CA3102967A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition de prostaglandine et un procédé de traitement de l'hypertension artérielle pulmonaire. La composition est à base de dicétopipérazine pour inhalation pulmonaire.
CA3102967A 2018-06-07 2019-06-07 Composition et procede d'inhalation Pending CA3102967A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682109P 2018-06-07 2018-06-07
US62/682,109 2018-06-07
PCT/US2019/036095 WO2019237028A1 (fr) 2018-06-07 2019-06-07 Composition et procédé d'inhalation

Publications (1)

Publication Number Publication Date
CA3102967A1 true CA3102967A1 (fr) 2019-12-12

Family

ID=68770678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102967A Pending CA3102967A1 (fr) 2018-06-07 2019-06-07 Composition et procede d'inhalation

Country Status (5)

Country Link
EP (1) EP3801552A4 (fr)
JP (1) JP2021527058A (fr)
AU (2) AU2019282808B2 (fr)
CA (1) CA3102967A1 (fr)
WO (1) WO2019237028A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255394A4 (fr) * 2020-12-07 2024-10-09 MannKind Corporation Procédé et composition pour le traitement de la fibrose pulmonaire

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031604B1 (ru) 2013-10-25 2019-01-31 Инсмед Инкорпорейтед Трепростинильные соединения, композиции и способы их использования
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
CN115916212A (zh) * 2020-04-17 2023-04-04 联合治疗公司 曲前列尼尔用于治疗间质性肺病
WO2021252446A1 (fr) 2020-06-09 2021-12-16 United Therapeutics Corporation Promédicaments à base de fumaryle dicétopipéridine de tréprostinil
AU2021369679A1 (en) * 2020-10-28 2023-05-18 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
US20220152025A1 (en) * 2020-11-17 2022-05-19 United Therapeutics Corporation Inhaled imatinib for pulmonary hypertension
WO2022187352A1 (fr) 2021-03-03 2022-09-09 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)
JP2025506019A (ja) 2022-02-08 2025-03-05 ユナイテッド セラピューティクス コーポレイション トレプロスチニルイロプロスト併用療法
WO2025160403A1 (fr) * 2024-01-24 2025-07-31 Mannkind Corporation Système de transport de poudre

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU2006290870B2 (en) * 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
WO2012174472A1 (fr) * 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
EP2970149B1 (fr) * 2013-03-15 2019-08-21 MannKind Corporation Compositions de dicétopipérazine microcristallines et procédés
WO2017132601A1 (fr) * 2016-01-29 2017-08-03 Mannkind Corporation Inhalateur à poudre sèche
IL262720B2 (en) * 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255394A4 (fr) * 2020-12-07 2024-10-09 MannKind Corporation Procédé et composition pour le traitement de la fibrose pulmonaire

Also Published As

Publication number Publication date
JP2021527058A (ja) 2021-10-11
AU2019282808A1 (en) 2021-01-07
WO2019237028A1 (fr) 2019-12-12
EP3801552A1 (fr) 2021-04-14
AU2025202053A1 (en) 2025-04-10
EP3801552A4 (fr) 2022-02-23
AU2019282808B2 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
AU2019282808B2 (en) Composition and method for inhalation
AU2022224822B2 (en) Dry powder inhaler
US20190321290A1 (en) Composition and method for inhalation
US20240180897A1 (en) Methods and compositions for treating pulmonary hypertension
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
US20220241271A1 (en) Inhalable dry powders
US20250288515A1 (en) Method and composition for treating lung diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240220

EEER Examination request

Effective date: 20240220